HOME >> BIOLOGY >> NEWS
AVANT to develop an oral anthrax and plague vaccine for U.S. Department of Defense

This release has been updated as of Monday January 21st.

NEEDHAM, MA (January 22, 2003): AVANT Immunotherapeutics, Inc. (Nasdaq: AVAN) today announced it has been awarded a subcontract to develop for the U.S. Department of Defense an oral combination vaccine against anthrax and plague using AVANT's proprietary vaccine technologies. Under the agreement, AVANT may receive in excess of $8 million over a two-year period, covering vaccine development through preclinical testing. AVANT executed the subcontract with DynPort Vaccine Company LLC ("DVC"), the prime contractor for the Defense Department's Joint Vaccine Acquisition Program (JVAP). Headquartered in Fort Detrick, MD, JVAP is the lead Defense Department organization for the development and purchase of vaccines for the U.S. military.

"This contract represents one of the first awards from a major U.S. Department of Defense (DoD) initiative to apply modern biotechnological innovations to the development of vaccines that can offer rapid, effective protection from multiple biological agents," said Una S. Ryan, Ph.D., President and Chief Executive Officer of AVANT Immunotherapeutics, Inc. "Current vaccines against bacterial bioweapons like anthrax (Bacillus anthracis) and plague (Yersinia pestis) require a protracted dosing regimen or provide only limited protection, and each vaccine protects against only a single agent. The Defense Department is looking for new, improved generation vaccines that are effective, single-dose, and can protect against multiple agents. The choice of AVANT to conduct this development program is an important recognition of the strength of AVANT's vaccine and vector technologies for accomplishing these aims."

"This contract is very important to AVANT since it provides non-dilutive funding to the company and it means that AVANT now has over two years of cash and cash equivalents on hand," Dr. Ryan concluded.

Senator Edward M. Kennedy (D-MA), Ranking Dem
'"/>

Contact: Joan Kureczka
JKureczka@aol.com
415-281-2413
Kureczka/Martin Associates
22-Jan-2003


Page: 1 2 3 4

Related biology news :

1. Clinical results with AVANT rotavirus vaccine demonstrate nearly 90% protection in young children
2. NIH awards $18.2m to The Burnham Institute to develop Center on Proteolytic Pathways
3. Schepens Eye Research Institute receives Roadmap grant to develop center for curing eye diseases
4. Wisconsin scientists develop quick botox test
5. Bronfenbrenner book sums up human development
6. Researchers develop fast track way to discover how cells are regulated
7. DuPont developing new protective suits for military, first responders
8. OutFoxed! New research may redefine late-stage cardiac development
9. Computer scientists at UH developing nurturing computers
10. Disease diagnosis, drug development focus of UH profs biochip research
11. Columbia, Stony Brook, Guidant to develop biological pacemaker based on gene & cell therapies

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/24/2017)... -- Research and Markets has announced the addition of ... - Industry Forecast to 2025" report to their offering. ... The Global Biometric Vehicle ... around 15.1% over the next decade to reach approximately $1,580 million ... estimates and forecasts for all the given segments on global as ...
(Date:3/22/2017)... , March 21, 2017   Neurotechnology , ... recognition technologies, today announced the release of the ... which provides improved facial recognition using up to ... a single computer. The new version uses deep ... accuracy, and it utilizes a Graphing Processing Unit ...
(Date:3/20/2017)... At this year,s CeBIT Chancellor Dr. Angela ... The Chancellor came to the DERMALOG stand together with the Japanese Prime ... partner country. At the largest German biometrics company the two government leaders ... iris recognition as well as DERMALOG´s multi-biometrics system.   ... ...
Breaking Biology News(10 mins):
(Date:4/28/2017)... ... 2017 , ... Cynvenio Biosystems, Inc. a leader in personalized medicine ... monitoring (NEAT) study in partnership with Allentown, PA-based TME Research . The multi-center ... monitored over two years with Cynvenio’s ClearID Breast Cancer blood test. The study goal ...
(Date:4/27/2017)... ... April 27, 2017 , ... ... digital pathology, today announced their digital pathology technology has the potential to eliminate ... five medical centers in The Netherlands as part of the 2017 ISBI ...
(Date:4/27/2017)... ... April 27, 2017 , ... Sierra Instruments ... on capillary thermal mass flow technology provide exponentially more accurate mass flow data ... 80% of all industrial processes—such as those involving chemical reactions, combustion, respiration, pharmaceutical, ...
(Date:4/27/2017)... 2017  Kinexum, a distinguished resource for research, development ... appointment of Thomas C. Seoh as President ... Kinexum founder, who becomes Executive Chairman and will continue ... Thomas Seoh commented, "I am ... and lead the firm,s remarkable team of life science ...
Breaking Biology Technology:
Cached News: